NASDAQ:RDUS - Radius Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$29.17 +0.47 (+1.64 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$29.17
Today's Range$28.75 - $29.69
52-Week Range$24.66 - $49.16
Volume735,619 shs
Average Volume816,668 shs
Market Capitalization$1.31 billion
P/E Ratio-5.03
Dividend YieldN/A
Beta1.27

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000

Debt

Debt-to-Equity Ratio0.87
Current Ratio6.55
Quick Ratio6.41

Price-To-Earnings

Trailing P/E Ratio-5.03
Forward P/E Ratio-5.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.11 million
Price / Sales59.98
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book6.80

Profitability

EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net Margins-706.11%
Return on Equity-108.95%
Return on Assets-64.23%

Miscellaneous

Employees561
Outstanding Shares45,460,000

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health (NASDAQ:RDUS) released its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.46) by $0.09. The biopharmaceutical company earned $14.50 million during the quarter, compared to analysts' expectations of $13.80 million. Radius Health had a negative return on equity of 108.95% and a negative net margin of 706.11%. During the same quarter last year, the business posted ($1.32) earnings per share. View Radius Health's Earnings History.

What price target have analysts set for RDUS?

9 brokers have issued 1 year price targets for Radius Health's shares. Their forecasts range from $31.00 to $85.00. On average, they anticipate Radius Health's share price to reach $54.25 in the next twelve months. View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)
  • 2. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Forteo and Prolia. Further, the company suffered a setback when the CHMP issued a negative trend vote on the benefit-risk balance for the MAA for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The delay in getting approval in Europe is disappointing given the market potential. The company’s shares have underperformed the industry in the last three months. Meanwhile, estimates are stable ahead of the first-quarter results (scheduled on May 8)." (5/2/2018)
  • 3. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Dr. Gregory Williams Ph.D., MBA, Chief Devel. Officer (Age 59)
  • Dr. Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 64)
  • Mr. Brian Nicholas Harvey, Advisor (Age 57)
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
  • Dr. Stavros C. Manolagas M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board

Has Radius Health been receiving favorable news coverage?

Media coverage about RDUS stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Radius Health earned a media sentiment score of 0.21 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Radius Health's major shareholders?

Radius Health's stock is owned by many different of institutional and retail investors. Top institutional investors include BB Biotech AG (12.94%), Farallon Capital Management LLC (8.99%), MPM Asset Management LLC (8.84%), Point72 Asset Management L.P. (4.05%), OppenheimerFunds Inc. (1.84%) and Franklin Resources Inc. (0.82%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., DekaBank Deutsche Girozentrale, Franklin Resources Inc., Sei Investments Co., Russell Investments Group Ltd., Teacher Retirement System of Texas and Guggenheim Capital LLC. View Insider Buying and Selling for Radius Health.

Which major investors are buying Radius Health stock?

RDUS stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., BB Biotech AG, Farallon Capital Management LLC, Eversept Partners LLC, MPM Asset Management LLC, Spark Investment Management LLC, UBS Group AG and Candriam Luxembourg S.C.A.. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $29.17.

How big of a company is Radius Health?

Radius Health has a market capitalization of $1.31 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]


MarketBeat Community Rating for Radius Health (RDUS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Radius Health (NASDAQ:RDUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Radius Health in the last 12 months. Their average twelve-month price target is $54.25, suggesting that the stock has a possible upside of 85.98%. The high price target for RDUS is $85.00 and the low price target for RDUS is $31.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.642.602.63
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.25$52.10$51.7778$51.00
Price Target Upside: 85.98% upside51.59% upside47.26% upside76.10% upside

Radius Health (NASDAQ:RDUS) Consensus Price Target History

Price Target History for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Cantor FitzgeraldReiterated RatingBuy$58.00HighView Rating Details
3/29/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$53.00MediumView Rating Details
3/23/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$61.00 ➝ $59.00LowView Rating Details
2/12/2018JPMorgan Chase & Co.Lower Price TargetOverweight$70.00 ➝ $60.00MediumView Rating Details
1/22/2018CitigroupReiterated RatingHold$43.00MediumView Rating Details
11/3/2017Jefferies GroupLower Price TargetHold$38.00 ➝ $31.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$45.00N/AView Rating Details
9/29/2017Maxim GroupReiterated RatingPositiveMediumView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$85.00MediumView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017CowenDowngradeOutperform ➝ Market PerformLowView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Radius Health (NASDAQ:RDUS) Earnings History and Estimates Chart

Earnings by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) Earnings Estimates

2018 EPS Consensus Estimate: ($5.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.32)($1.32)($1.32)
Q2 20181($1.29)($1.29)($1.29)
Q3 20181($1.30)($1.30)($1.30)
Q4 20181($1.26)($1.26)($1.26)

Radius Health (NASDAQ RDUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1($1.46)($1.37)$13.80 million$14.50 millionViewN/AView Earnings Details
3/1/2018Q4 2017($1.43)($1.59)$7.37 million$7.66 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.28)($1.31)$6.90 million$13.50 millionViewN/AView Earnings Details
8/3/2017Q2 2017($1.35)($1.58)$1.96 million$0.98 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.1820)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Radius Health (NASDAQ:RDUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.42%
Insider Trading History for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ RDUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2018Growth N V BiotechMajor ShareholderBuy40,000$28.91$1,156,400.006,150,913View SEC Filing  
5/21/2018Growth N V BiotechMajor ShareholderBuy60,000$29.27$1,756,200.006,110,913View SEC Filing  
4/19/2018Growth N V BiotechMajor ShareholderBuy40,000$33.80$1,352,000.006,050,913View SEC Filing  
4/5/2018Growth N V BiotechMajor ShareholderBuy50,000$36.58$1,829,000.005,903,799View SEC Filing  
3/2/2018Growth N V BiotechMajor ShareholderBuy80,000$32.52$2,601,600.005,853,799View SEC Filing  
2/9/2018Growth N V BiotechMajor ShareholderBuy75,000$34.38$2,578,500.005,773,799View SEC Filing  
11/14/2017Growth N V BiotechMajor ShareholderBuy50,000$26.25$1,312,500.005,698,799View SEC Filing  
11/10/2017Brent Hatzis-SchochVPBuy1,778$28.09$49,944.022,278View SEC Filing  
11/7/2017Jesper HoilandInsiderBuy6,800$29.04$197,472.0012,900View SEC Filing  
11/3/2017Growth N V BiotechMajor ShareholderBuy50,000$29.15$1,457,500.005,648,799View SEC Filing  
10/25/2017Growth N V BiotechMajor ShareholderBuy50,000$32.85$1,642,500.005,548,799View SEC Filing  
9/15/2017Jesper HoilandInsiderBuy6,100$32.72$199,592.006,100View SEC Filing  
9/14/2017Growth N V BiotechMajor ShareholderBuy150,000$33.45$5,017,500.005,448,799View SEC Filing  
9/14/2017Jose CarmonaCFOBuy3,000$32.83$98,490.003,000View SEC Filing  
9/12/2017Growth N V BiotechMajor ShareholderBuy50,000$35.42$1,771,000.005,348,799View SEC Filing  
9/5/2017Growth N V BiotechMajor ShareholderBuy50,000$36.75$1,837,500.005,298,799View SEC Filing  
8/16/2017Growth N V BiotechMajor ShareholderBuy60,000$35.98$2,158,800.005,248,799View SEC Filing  
8/10/2017Growth N V BiotechMajor ShareholderBuy150,000$34.97$5,245,500.005,113,799View SEC Filing  
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.005,038,799View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.004,998,799View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.004,958,799View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.004,890,799View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.004,873,799View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.004,858,799View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.004,785,999View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.004,765,399View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.004,690,399View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.004,540,399View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.004,490,399View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.374,415,930View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.434,398,678View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.534,360,399View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.004,322,140View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.004,272,140View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Radius Health (NASDAQ RDUS) News Headlines

Source:
DateHeadline
Insider Buying: Radius Health (RDUS) Major Shareholder Buys 40,000 Shares of StockInsider Buying: Radius Health (RDUS) Major Shareholder Buys 40,000 Shares of Stock
www.americanbankingnews.com - May 24 at 4:17 PM
Radius Health (RDUS) Receives Consensus Recommendation of "Hold" from AnalystsRadius Health (RDUS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 24 at 11:55 AM
Radius Health Forecasted to Post FY2018 Earnings of ($4.81) Per Share (RDUS)Radius Health Forecasted to Post FY2018 Earnings of ($4.81) Per Share (RDUS)
www.americanbankingnews.com - May 24 at 8:22 AM
Radius Health (RDUS) Major Shareholder Growth N. V. Biotech Acquires 60,000 SharesRadius Health (RDUS) Major Shareholder Growth N. V. Biotech Acquires 60,000 Shares
www.americanbankingnews.com - May 23 at 4:17 PM
Radius Health Enters Oversold Territory (RDUS)Radius Health Enters Oversold Territory (RDUS)
www.nasdaq.com - May 21 at 4:57 PM
 Analysts Expect Radius Health (RDUS) Will Announce Quarterly Sales of $20.27 Million Analysts Expect Radius Health (RDUS) Will Announce Quarterly Sales of $20.27 Million
www.americanbankingnews.com - May 21 at 3:04 AM
Zacks: Brokerages Expect Radius Health (RDUS) Will Post Earnings of -$1.32 Per ShareZacks: Brokerages Expect Radius Health (RDUS) Will Post Earnings of -$1.32 Per Share
www.americanbankingnews.com - May 19 at 1:23 PM
Radius Health (RDUS) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - SlideshowRadius Health (RDUS) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 16 at 5:14 PM
Radius Health (RDUS) Announces Quarterly  Earnings ResultsRadius Health (RDUS) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 10:21 PM
Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare ConferenceRadius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference
feeds.benzinga.com - May 11 at 9:52 PM
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 LossRadius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss
finance.yahoo.com - May 11 at 5:27 PM
Radius Healths (RDUS) Buy Rating Reiterated at Cantor FitzgeraldRadius Health's (RDUS) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - May 11 at 3:57 PM
Edited Transcript of RDUS earnings conference call or presentation 10-May-18 12:00pm GMTEdited Transcript of RDUS earnings conference call or presentation 10-May-18 12:00pm GMT
finance.yahoo.com - May 11 at 9:06 AM
Radius Health beats by $0.09, beats on revenueRadius Health beats by $0.09, beats on revenue
seekingalpha.com - May 10 at 8:50 AM
Radius Health: 1Q Earnings SnapshotRadius Health: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:50 AM
Whats in Store for Radius Health (RDUS) in Q1 Earnings?What's in Store for Radius Health (RDUS) in Q1 Earnings?
finance.yahoo.com - May 7 at 5:18 PM
What's in Store for Radius Health (RDUS) in Q1 Earnings?What's in Store for Radius Health (RDUS) in Q1 Earnings?
finance.yahoo.com - May 7 at 5:18 PM
Radius Health (RDUS) Expected to Announce Quarterly Sales of $13.81 MillionRadius Health (RDUS) Expected to Announce Quarterly Sales of $13.81 Million
www.americanbankingnews.com - May 4 at 4:40 AM
Radius Health (RDUS) to Release Quarterly Earnings on ThursdayRadius Health (RDUS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 3:50 AM
Radius Health (RDUS) Raised to Hold at ValuEngineRadius Health (RDUS) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
Radius Health (RDUS) Stock Rating Lowered by Zacks Investment ResearchRadius Health (RDUS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 2 at 1:35 PM
Radius Health (RDUS) Downgraded by BidaskClubRadius Health (RDUS) Downgraded by BidaskClub
www.americanbankingnews.com - May 2 at 1:10 PM
-$1.40 Earnings Per Share Expected for Radius Health (RDUS) This Quarter-$1.40 Earnings Per Share Expected for Radius Health (RDUS) This Quarter
www.americanbankingnews.com - May 2 at 1:22 AM
Radius Health (RDUS) Given Average Rating of "Hold" by BrokeragesRadius Health (RDUS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 29 at 8:16 AM
Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10 ...Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10 ...
globenewswire.com - April 26 at 5:02 PM
Radius Health (RDUS) Rating Lowered to Sell at ValuEngineRadius Health (RDUS) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 26 at 1:32 PM
Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018
finance.yahoo.com - April 24 at 8:39 AM
Insider Buying: Radius Health (RDUS) Major Shareholder Acquires 40,000 Shares of StockInsider Buying: Radius Health (RDUS) Major Shareholder Acquires 40,000 Shares of Stock
www.americanbankingnews.com - April 23 at 4:24 PM
Radius Health (RDUS) Downgraded to Hold at BidaskClubRadius Health (RDUS) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM
Radius Health Target of Unusually High Options Trading (RDUS)Radius Health Target of Unusually High Options Trading (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM
Stock Traders Buy High Volume of Call Options on Radius Health (RDUS)Stock Traders Buy High Volume of Call Options on Radius Health (RDUS)
www.americanbankingnews.com - April 19 at 8:00 AM
Radius Health (RDUS) PT Set at $65.00 by Cantor FitzgeraldRadius Health (RDUS) PT Set at $65.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 10:21 PM
Radius Health (RDUS) Given a $85.00 Price Target by Canaccord Genuity AnalystsRadius Health (RDUS) Given a $85.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 17 at 10:21 PM
Radius Health (RDUS) Expected to Post Quarterly Sales of $13.81 MillionRadius Health (RDUS) Expected to Post Quarterly Sales of $13.81 Million
www.americanbankingnews.com - April 17 at 4:59 AM
Cantor Fitzgerald Reiterates $58.00 Price Target for Radius Health (RDUS)Cantor Fitzgerald Reiterates $58.00 Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 16 at 10:22 PM
Canaccord Genuity Reiterates "$85.00" Price Target for Radius Health (RDUS)Canaccord Genuity Reiterates "$85.00" Price Target for Radius Health (RDUS)
www.americanbankingnews.com - April 15 at 8:37 AM
 Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS
www.americanbankingnews.com - April 15 at 3:11 AM
Zacks Investment Research Upgrades Radius Health (RDUS) to HoldZacks Investment Research Upgrades Radius Health (RDUS) to Hold
www.americanbankingnews.com - April 12 at 7:25 PM
Growth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) StockGrowth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) Stock
www.americanbankingnews.com - April 9 at 4:11 PM
Q1 2018 EPS Estimates for Radius Health Decreased by Analyst (RDUS)Q1 2018 EPS Estimates for Radius Health Decreased by Analyst (RDUS)
www.americanbankingnews.com - April 9 at 1:19 AM
UPDATE: Leerink Partners Starts Radius Health (RDUS) at OutperformUPDATE: Leerink Partners Starts Radius Health (RDUS) at Outperform
www.streetinsider.com - April 7 at 8:58 AM
Radius Health Inc (RDUS) Given Average Rating of "Buy" by BrokeragesRadius Health Inc (RDUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 9:12 AM
Radius Health (RDUS) Lifted to "Hold" at ValuEngineRadius Health (RDUS) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 12:32 AM
Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 2 at 9:06 AM
Is Radius Health Worth Your Time?Is Radius Health Worth Your Time?
seekingalpha.com - March 31 at 8:38 AM
 Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million
www.americanbankingnews.com - March 31 at 4:16 AM
Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male OsteoporosisRadius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
finance.yahoo.com - March 30 at 5:11 PM
Radius Health (RDUS) Raised to "Hold" at BidaskClubRadius Health (RDUS) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM
Radius Health (RDUS) Now Covered by Leerink SwannRadius Health (RDUS) Now Covered by Leerink Swann
www.americanbankingnews.com - March 29 at 8:36 AM
 Analysts Anticipate Radius Health Inc (RDUS) Will Announce Earnings of -$1.42 Per Share Analysts Anticipate Radius Health Inc (RDUS) Will Announce Earnings of -$1.42 Per Share
www.americanbankingnews.com - March 29 at 5:17 AM

SEC Filings

Radius Health (NASDAQ:RDUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Radius Health (NASDAQ RDUS) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.